Lung cancer screening: Improved survival but no reduction in deaths - The role of 'overdiagnosis'

Cancer

Volumn 89, Issue 11 SUPPL., 2000, Pages 2369-2376

  MaxwellParkin, D ^a   Moss, Sue M ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bias; Breast; Cervix; Lung cancer screening; Neuroblastoma; Overdiagnosis; Prostate; Randomized controlled trials

Indexed keywords

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; EARLY CANCER; LUNG CANCER; NEUROBLASTOMA; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0034548751     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001201)89:11+<2369::aid-cncr10>3.3.co;2-1     Document Type: Conference Paper

References (55)

1. Concepts and problems in the evaluation of screening programmes
2. First results on mortality reduction in the UK trial of early detection of breast cancer
3. A case-control evaluation of the effect of breast cancer screening in the United Kingdom trial of early detection of breast cancer
4. IARC working group on cervical cancer screening 1986
5. Screening for lung cancer - Results from a case-control study
6. Screening for lung cancer in the middle-aged
7. A case-control study for evaluating lung-cancer screening in Japan
8. Calculation of sample size of trials of screening for early diagnosis of disease
9. Surrogate endpoints in clinical trials: Definition and operational criteria
10. Breast cancer screening programmes: The development of a monitoring and evaluation system
11. Breast screening, prognostic factors and survival - Results from the Swedish two county study
12. Intermediate determinants of mortality in the evaluation of screening
13. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
14. Survival of patients with colorectal cancer diagnosed in a randomised controlled trial of faecal occult blood screening
15. Lung cancer screening and randomized population trials
16. Screening for lung cancer
17. A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR
18. Multiphasic Health Checkup Evaluation: A 16-year follow-up
19. Screening for lung cancer. A critique of the Mayo Lung Project
20. The value of lung cancer detection by six-monthly chest radiographs
21. Lack of benefit from semi-annual screening for cancer of the lung: Follow-up of a randomized controlled trial on a population of high risk males in Czechoslovakia
22. Current results of the breast cancer screening randomized trial: The health insurance plan (HIP) of greater New York Study
23. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish Board of Health and Welfare
24. Evaluation of the results
25. Efficacy of breast cancer screening by age
26. The Gothenburg breast screening trial: First results on mortality, incidence, and mode of detection for women aged 39-49 years at randomization
27. Mammographic screening and mortality from breast cancer: The Malmo mammographic screening trial
28. Results from the NHS breast screening programme 1990-1993
29. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: A dilemma
30. Longitudinal screening for prostate cancer with prostate-specific antigen
31. Latent carcinoma of prostate at autopsy in seven areas
32. Geographic pathology of latent prostatic carcinoma
33. Characteristics of prostate cancer found with early detection regimens
34. The nature of prostate cancer detected through prostate specific antigen based screening
35. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales
36. The role of increasing detection in the rising incidence of prostate cancer
37. Changes in prostate cancer incidence and treatment in USA
38. Cancer mortality rates fall: A turning point for the nation
39. Evaluation of screening for prostate, lung and colorectal cancer: The PLC trial
40. Prospective evaluation plan for randomised trials of prostate cancer screening
41. Neuroblastoma: Influence of age at diagnosis, stage, tumor site, and sex on prognosis
42. Neuroblastoma. Mass screening for early detection and its prognosis
43. Effects of mass screening on age-specific incidence of neuroblastoma
44. Mass screening and age-specific incidence of neuroblastoma in Saitani Prefecture, Japan
45. Biology of neuroblastomas in Japan found by screening
46. Flow cytometric DNA analysis of neuroblastoma: Prognostic significance of DNA ploidy in unfavorable group
47. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients
48. Screening for neuroblastoma is ineffective in reducing the incidence of infavourable advanced stage disease in older children
49. Spontaneous regression of localised neuroblastoma detected by mass screening
50. Stage I NSCLC: Analysis of survival
51. The 'epidemiologic necropsy'. Unexpected detections, demographic selections, and changing rates of lung cancer
52. More lung cancer but better survival. Implications of secular trends in 'necropsy surprise' rates
53. Implications of tumor growth rate for the natural history of lung cancer
54. The natural history of lung cancer estimated from the results of a randomized trial of screening
55. Screening for lung cancer